Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review
ConclusionExposure to DRV increases modestly with age, while exposure to BIC, DOR and RAL appears to be unaffected by age. As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - August 10, 2023 Category: Drugs & Pharmacology Source Type: research
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
ConclusionDolutegravir/lamivudine had the lowest healthcare costs of BIC/FTC/TAF, EVG/COBI/FTC/TAF, and DRV/COBI/FTC/TAF, and the lowest pharmacy costs of all regimens, in unadjusted and adjusted analyses and by treatment experience, supporting the economic benefits of DTG/3TC as an initial or switch regimen for HIV-1. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - August 8, 2023 Category: Infectious Diseases Source Type: research
Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy
AIDS Research and Human Retroviruses, Ahead of Print. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - August 2, 2023 Category: Infectious Diseases Authors: Damiano Farinacci Valentina Iannone Anna D'Angelillo Alberto Borghetti Rosa Anna Passerotto Francesco Lamanna Simona Di Giambenedetto Source Type: research
Endothelial Glycocalyx Integrity in Treatment-Na ïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation
This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.PMID:37515191 | PMC:PMC10383742 | DOI:10.3390/v15071505 (Source: Atherosclerosis)
Source: Atherosclerosis - July 29, 2023 Category: Cardiology Authors: Paraskevi C Fragkou Ignatios Ikonomidis Dimitrios Benas Dimitra Kavatha Charalampos D Moschopoulos Konstantinos Protopapas Gavriella Kostelli John Thymis Dionysia Mpirmpa Irene Galani Maria Tsakona Chrysanthi Oikonomopoulou George Theocharous Vassilis G G Source Type: research
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Na ïve People Living with HIV-1
(Source: ClinicoEconomics and Outcomes Research)
Source: ClinicoEconomics and Outcomes Research - July 24, 2023 Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
Viruses, Vol. 15, Pages 1505: Endothelial Glycocalyx Integrity in Treatment-Na & iuml;ve People Living with HIV before and One Year after Antiretroviral Treatment Initiation
This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH. (Source: Viruses)
Source: Viruses - July 5, 2023 Category: Virology Authors: Paraskevi C. Fragkou Ignatios Ikonomidis Dimitrios Benas Dimitra Kavatha Charalampos D. Moschopoulos Konstantinos Protopapas Gavriella Kostelli John Thymis Dionysia Mpirmpa Irene Galani Maria Tsakona Chrysanthi Oikonomopoulou George Theocharous Vassilis G Tags: Article Source Type: research
Quality by design tool-evaluated stability-indicating ultra-performance liquid chromatography method for the determination of drugs (ritonavir and darunavir) used to treat the human immunodeficiency virus/acquired immunodeficiency syndrome
Biomed Chromatogr. 2023 Jul 1:e5687. doi: 10.1002/bmc.5687. Online ahead of print.ABSTRACTRitonavir and darunavir were examined using a ultra-performance liquid chromatography (UPLC) approach in pharmaceutical dosage forms. The small number of analytical studies that are currently available do not demonstrate the method's stability or nature. The study sought to assess both chemicals using a stability-indicating approach with a relatively short run time. The HSS C18 (100 × 2.1 mm), 2-mm column was used for the chromatographic separation, and isocratic elution was used to achieve this. In the mobile phase, methanol and 0.0...
Source: Biomedical Chromatography : BMC - July 1, 2023 Category: Biomedical Science Authors: Jyothsna Menda Phani Raja Kanuparthy Naresh Kumar Katari Leela Prasad Kowtharapu Santhosh Kumar Ettaboina Surya Prakash Rao Pydimarry Source Type: research
Quality by design tool-evaluated stability-indicating ultra-performance liquid chromatography method for the determination of drugs (ritonavir and darunavir) used to treat the human immunodeficiency virus/acquired immunodeficiency syndrome
Biomed Chromatogr. 2023 Jul 1:e5687. doi: 10.1002/bmc.5687. Online ahead of print.ABSTRACTRitonavir and darunavir were examined using a ultra-performance liquid chromatography (UPLC) approach in pharmaceutical dosage forms. The small number of analytical studies that are currently available do not demonstrate the method's stability or nature. The study sought to assess both chemicals using a stability-indicating approach with a relatively short run time. The HSS C18 (100 × 2.1 mm), 2-mm column was used for the chromatographic separation, and isocratic elution was used to achieve this. In the mobile phase, methanol and 0.0...
Source: Biomedical Chromatography : BMC - July 1, 2023 Category: Biomedical Science Authors: Jyothsna Menda Phani Raja Kanuparthy Naresh Kumar Katari Leela Prasad Kowtharapu Santhosh Kumar Ettaboina Surya Prakash Rao Pydimarry Source Type: research
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study
Future Virology, Ahead of Print. (Source: Future Virology)
Source: Future Virology - June 22, 2023 Category: Virology Authors: Andrea Antinori Alessandra Vergori Diego Ripamonti Daniela Valenti Giuliano Rizzardini Maria Vittoria Cossu Stefano Rusconi Vincenzo Esposito Antonio Cascio Giancarlo Orofino Massimo Andreoni Elio Manzillo Antonella Castagna Daniela Mancusi Roberta Termin Source Type: research
Bioequivalence of a Pediatric Fixed ‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study
In conclusion, administration of D/C/F/TAF 675/150/200/10-mg FDC was bioequivalent to coadministration of the separate commercially available formula tions. (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - June 20, 2023 Category: Drugs & Pharmacology Authors: Sandy Van Hemelryck,
Erika Van Landuyt,
Jay Ariyawansa,
Simon Vanveggel,
Martyn Palmer Tags: Original Article Source Type: research
Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
CONCLUSIONS: Over a short average follow-up period of <2 years, INSTI use among treatment-naïve PLWH was associated with an increased risk of several cardiometabolic outcomes, such as CHF, myocardial infarction and lipid disorders, compared to non-INSTI use. Further research accounting for additional potential confounders and with longer follow-up is warranted to more accurately and precisely quantify the impact of INSTI-containing ART on long-term cardiometabolic outcomes.PMID:37306118 | DOI:10.1002/jia2.26123 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - June 12, 2023 Category: Infectious Diseases Authors: Peter F Rebeiro Bruno Emond Carmine Rossi Brahim K Bookhart Aditi Shah Gabrielle Caron-Lapointe Marie-H élène Lafeuille Prina Donga Source Type: research
Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities
This study examined the most recent evidence on the efficacy and safety of several therapeutic options available including natural substances, synthetic drugs and vaccines in the treatment of COVID-19. Various natural compounds such as sarsapogenin, lycorine, biscoclaurine, vitamin B12, glycyrrhizic acid, riboflavin, resveratrol and kaempferol, various vaccines and drugs such as AZD1222, mRNA-1273, BNT162b2, Sputnik V, and remdesivir, lopinavir, favipiravir, darunavir, oseltamivir, and umifenovir, resp., have been discussed comprehensively. We attempted to provide exhaustive information regarding the various prospective th...
Source: Acta Pharmaceutica - June 12, 2023 Category: Drugs & Pharmacology Authors: Sijia Fan Hongling Wang Dean Wu Lu Liu Source Type: research
